Recently, Aetna, which is one of the largest insurance companies in the United States, announced it would reimburse PAs at 85 percent of the physician pay schedule. So what does this move mean for PAs? Michael Powe, vice president of health systems reimbursement policy for the American Academy of Physician Assistants, joins host Lisa Dandrea Lenell to look at the current reimbursement picture and how PAs can make sure they are being reimbursed for the care they provide. They also look at how this process could change in the future with healthcare reform.
Recent Developments in Medical Billing and Reimbursement for PAs
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Recently, Aetna, which is one of the largest insurance companies in the United States, announced it would reimburse PAs at 85 percent of the physician pay schedule. So what does this move mean for PAs? Michael Powe, vice president of health systems reimbursement policy for the American Academy of Physician Assistants, joins host Lisa Dandrea Lenell to look at the current reimbursement picture and how PAs can make sure they are being reimbursed for the care they provide. They also look at how this process could change in the future with healthcare reform.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
FCS and SHTG: Are We Meeting the Need?
0.25 credits
<p>FCS and SHTG: Are We Meeting the Need?</p>
CME/CE Broadcast Replay
Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease
1.00 credits
<p>Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease</p>
CME/CE
IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement
0.50 credits
<p>IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement</p>
NeuroFrontiers
Navigating Myasthenia Gravis in Adolescents and Young Adults
<p>Navigating Myasthenia Gravis in Adolescents and Young Adults</p>
NeuroFrontiers
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
<p>Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids</p>
Cardiology
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
<p>Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF</p>
Cardiology
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
<p>Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial </p>
Cardiology
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
<p>Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?